Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.
about
Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapyA Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V).Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidenceA Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy.Quantitative determination of saroglitazar, a predominantly PPAR alpha agonist, in human plasma by a LC-MS/MS method utilizing electrospray ionization in a positive mode.Saroglitazar for the treatment of dyslipidemia in diabetic patients.Targeting high-density lipoproteins: increasing de novo production versus decreasing clearance.Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.Multitargeted bioactive ligands for PPARs discovered in the last decade.The therapeutic landscape of non-alcoholic steatohepatitis.The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases.From 'Make in India' to 'Made in India': the saroglitazar story.Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus.Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders.Virtual identification of novel PPARα/γ dual agonists by scaffold hopping of saroglitazar.Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.
P2860
Q24564203-C8932274-5213-4F05-8806-A88A386097F3Q24616813-6E135750-F6CE-4BC0-8336-91B95F937F37Q35329472-25BC7D7E-2FB2-4552-927A-F09D08E7C9E1Q35492306-12A6E5AE-EFBB-46A1-9E30-677790C37506Q35899038-F8063E72-44AF-4A14-B8FB-E66FD543D4C7Q36019949-85827B55-5432-4010-9029-3406DF842E09Q38352759-127F7C6A-151E-4673-93AE-C5A038717AE5Q38431166-2768DB8C-A505-4283-A912-4A6B6018F663Q38580461-B426F8E9-96BA-4FAF-860B-4998DE6B6C05Q38869029-CDF6042A-3A24-4785-BB70-42C8FB05C84BQ38978011-5C78A522-19EE-4FA9-93E6-4DB90A20A419Q39185669-E189A97E-2A9A-498B-8CE5-3E4A2CC77C1AQ42559674-5BAD470E-B7F9-4434-9332-83F64D237AAEQ42696420-5D432E52-E90C-4C78-A0E2-D1133AE44385Q46207930-AF79E810-8961-4A27-A15A-D1DE264B466AQ47311251-35DB766A-FF29-43FF-BBC9-B807DB270072Q47400859-1537F663-D2A7-4E89-8597-E38328C49852Q50136712-78C68F19-BF3F-4AC8-8C3B-AC908C4B2E29
P2860
Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Pharmacokinetics, safety, and ...... ity in healthy human subjects.
@en
Pharmacokinetics, safety, and ...... ity in healthy human subjects.
@nl
type
label
Pharmacokinetics, safety, and ...... ity in healthy human subjects.
@en
Pharmacokinetics, safety, and ...... ity in healthy human subjects.
@nl
prefLabel
Pharmacokinetics, safety, and ...... ity in healthy human subjects.
@en
Pharmacokinetics, safety, and ...... ity in healthy human subjects.
@nl
P2093
P2860
P1476
Pharmacokinetics, safety, and ...... vity in healthy human subjects
@en
P2093
Harilal Patel
Kevinkumar Kansagra
Mukul R Jain
P2860
P304
P356
10.1007/S40261-013-0128-3
P577
2013-11-01T00:00:00Z